Berrak zihinler için yalın, zengin, bağımsız bir Türkçe dijital medya üyeliği.
Ücretsiz Kaydol →
dolutegravir ile ilgili hikayeler
• GlaxoSmithKlein won damages of $1.25 billion (€1.1bn) from Gilead in a years-long legal dispute about the latter's drug HIV drug biktarvy , which GSK says infringes on the patent for their dolutegravir . Royalties: The global patent suit also yielded that Gilead would pay 3% royalties on all sales of biktarvy until GSK's dolutegravir patent expires in 2027.
03 Şub 2022